Drug developer Pharmos Corp. said Tuesday its postoperative pain treatment candidate showed mixed results in a midstage study.
The drug, an intravenous cannabinor, reduces pain versus placebo in a low-dose section of the Phase IIa clinical trial, at 12-milligrams, but failed to do so in higher doses of 24-milligrams and 48-milligrams.
"This is an unexpected pattern of results and the company continues to explore possible explanations," Pharmos (nasdaq: PARS - news - people ) said in a statement.
Shares of Pharmos rose 52 cents, or 35 percent, to $2.02 on the Nasdaq Stock Market (nasdaq: NDAQ - news - people ) in morning trading. The stock has traded between $1.36 and $2.58 over the last 52 weeks.
Tuesday, April 24, 2007
Pharmos: Mixed Trial Data
Forbes:
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment